Could one drug match two for ovarian cancer? trial tests gentler chemo approach

This study is testing whether paclitaxel chemotherapy alone works as well as the standard paclitaxel-carboplatin combination for advanced ovarian cancer patients with high levels of a specific gene called PARK2. Researchers want to see if using just one drug can reduce side effects and delay exposure to platinum-based drugs, which can cause resistance. The trial will enroll 60 women with advanced ovarian cancer who haven't had prior treatment and can't have immediate surgery.